Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8<sup>+</sup> T cells. [PDF]
Yang Y +14 more
europepmc +1 more source
Optimizing Oncolytic Virotherapy for Malignant Glioma: From Bench to Bedside. [PDF]
Jiang W, Tian Y, Gu H, Guan W.
europepmc +1 more source
The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. [PDF]
Smestad J, Rieth J, Laux D, Milhem M.
europepmc +1 more source
Editorial: Oncolytic virotherapy, volume II. [PDF]
Al-Shammari AM, Piccaluga PP.
europepmc +1 more source
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity. [PDF]
Hayes AJ +18 more
europepmc +1 more source
Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy. [PDF]
Dong Z +11 more
europepmc +1 more source
Extended Survival in a Dog with Primary Bone Hemangiosarcoma Following Treatment with Neoadjuvant Oncolytic Virotherapy and Standard of Care. [PDF]
Labé C +15 more
europepmc +1 more source
Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. [PDF]
Pannhausen J +9 more
europepmc +1 more source
A Mathematical Perspective on the Influence of Allee Effects in Oncolytic Virotherapy. [PDF]
Hernández-López E, Wang J.
europepmc +1 more source

